The Centers for Medicare & Medicaid Services has negotiated agreements with Vertex Pharmaceuticals and bluebird bio to include their sickle cell disease treatments, Casgevy and Lyfgenia, in a new Cell and Gene Therapy Access Model. This voluntary model allows states in the Medicaid Drug Rebate Program to apply for funding based on the drugs' effectiveness in improving patient outcomes. With over 100,000 individuals affected by sickle cell disease in the U.S., the initiative aims to enhance access to innovative therapies while providing budget predictability for state Medicaid agencies.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
